Physician profile
Erika Sullivan
NPI 1568828812
$8,283.33
in general payments reported to CMS, 2019-2025
32 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,059 · 2022: $921 · 2023: $1,807 · 2024: $2,473 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,303.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,609.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $785.11 | 2021-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $670.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $632.54 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $553.48 | 2023-2025 | Spravato |
| Pfizer INC. | $545.07 | 2021-2025 | |
| Novo Nordisk INC | $523.02 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $482.68 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $418.85 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Exact Sciences Corporation | $391.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $338.87 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $232.94 | 2022-2025 | |
| Axsome Therapeutics, INC. | $117.21 | 2025 | Auvelity, Symbravo |
| Eisai INC. | $97.81 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.01 | 2021-2024 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $82.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.97 | 2024-2025 | Jardiance |
| Amarin Pharma, INC. | $71.22 | 2021 | |
| Vanda Pharmaceuticals INC. | $62.67 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $54.49 | 2023-2024 | Shingrix, Arexvy |
| Corcept Therapeutics | $54.01 | 2025 | Korlym |
| Fidia Pharma USA INC. | $52.59 | 2024-2025 | Hymhyn, Hym/Hyn |
| Teva Pharmaceuticals USA, INC. | $50.18 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $44.27 | 2022 | |
| Impel Pharmaceuticals INC. | $43.63 | 2023 | Trudhesa |
| Biomerieux INC | $43.00 | 2025 | Biofire Spotfire Control Station |
| Radius Health, INC. | $34.69 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $31.96 | 2021-2022 | |
| Therapeuticsmd, INC. | $30.13 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.77 | 2025 | Eliquis |
| Horizon Therapeutics Plc | $19.36 | 2021 | |
| Grifols USA, LLC | $18.60 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.